BioCryst Pharmaceuticals is trading with a striking divergence this week: short interest remains historically elevated at 15.3% of the float, yet options traders are the most bullish they have been all year.
The options market is sending an unusually strong signal. The put/call ratio collapsed to 0.12 on Tuesday — nearly three standard deviations below its 20-day average of 0.19 and close to the 52-week low of 0.10. That reading reflects a sharp surge in call-side demand relative to puts, the most one-sided bullish options positioning BCRX has seen in at least a year. The move is particularly notable because it happened in a single session: the PCR had been running steadily near 0.21 for most of the past two weeks before falling sharply on August 25.
Short interest tells a more cautious story, and the two signals sitting side by side is the tension worth watching. At 15.3% of the free float — roughly 32.2 million shares — the short book remains substantial even after a dramatic unwind. As recently as late July, short interest topped 46.6 million shares, representing well over 20% of the float. That squeeze-like compression through August cut the position by nearly a third. Yet shorts have not surrendered entirely: the latest daily reading shows a 4.1% one-day uptick, and the week-on-week change is up 2.3%. Some sellers are rebuilding after being squeezed. The lending market, however, gives them little reason to panic — availability is extremely loose at 705%, meaning shares to borrow far outnumber existing short positions, and the cost to borrow is negligible at 0.64%. There is no mechanical pressure forcing short-sellers out.
The Street remains broadly constructive but is clearly in a price-discovery phase. Following the Q2 report in early August — which beat consensus on revenue at $218 million, boosted by a $56 million EU licensing deal for navenibart — both RBC Capital and Wedbush trimmed their targets slightly while holding Outperform ratings. JP Morgan reinstated in mid-July at Neutral with a $12 target, a notably cautious re-entry. The bull case centres on Orladeyo's pediatric formulation resuming growth after a manufacturing fix, and on navenibart efficacy data due in Q3 2027 that could reshape the HAE and rare disease narrative. Bears flag ongoing losses — the PE and price-to-book multiples are both distorted by negative book value — and the risk that pipeline bets do not convert on schedule. The consensus price target of $20.91 implies more than 100% upside to the current $9.83 close, though targets range from $12 to $32, suggesting genuine disagreement rather than herd consensus.
Institutional ownership adds a layer of credibility to the bull camp. BlackRock added 1.24 million shares in July, bringing its stake to 9.4% of the company. State Street added nearly 3 million shares in the same period. Perceptive Advisors, a specialist healthcare fund, built a 4% position with 2.9 million shares added. Against that institutional accumulation, insider activity over the past several months has leaned toward the sell side — the CEO, CLO, and CCO all sold shares between December and May — though most of those transactions appear to be routine programme sales rather than alarm-bell disposals. The insider data is now more than 90 days stale, so it should be treated as background context rather than a live signal.
The ORTEX short score of 61.2 is moderate rather than extreme, ranking in the 21st percentile on short-score rank — meaning the stock is not flagged as an acute squeeze candidate despite its elevated short interest. The next catalyst on the calendar is the Q3 earnings call on November 5. Between now and then, the key variable is whether the unusual burst of call-buying on August 25 reflects informed positioning ahead of a near-term catalyst or simply a low-volume options day distorting the PCR — and whether short-sellers use the loose borrow market to rebuild the position they rapidly unwound through July.
See the live data behind this article on ORTEX.
Open BCRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
